• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles 2019
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles 2019
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    One year effectiveness study of intravitreal aflibercept in neovascular age-related macular degeneration: a meta-analysis

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Guo, M.Y.
    Cheng, J.
    Etminan, M.
    Date
    2019
    Journal
    Acta Ophthalmologica
    Publisher
    Blackwell Publishing Ltd
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.1111/aos.13825
    Abstract
    The current body of evidence on the efficacy and safety of aflibercept for age‐related macular degeneration (AMD) is steadily growing as large clinical trials and observational studies are continually completed. Our aim was to analyse 1‐year visual acuity (VA) outcomes in response to aflibercept therapy and identify factors affecting treatment response using evidence generated from a pooled analysis of current studies. A literature review of multiple electronic databases (EMBASE, MEDLINE, MedMEME) revealed 12 studies meeting inclusion and exclusion criteria for statistical analysis. Treatment posology, baseline patient characteristics, study type, sample size and 12‐month change in VA were pooled in a meta‐analysis with VA change as the main outcome. Data were then stratified by study design and posology in subgroup analyses. A meta‐regression was conducted to regress 12‐month VA change against posology, baseline VA and age. Users of aflibercept experienced an overall increase of 7.37 letters (95% confidence interval: 6.27–8.48, p heterogeneity: <0.001) in VA at 12 months of follow‐up. In subgroup analyses, mean VA change was higher for randomized control trials and cohorts following regular posology (>7 injections/year) compared to observational studies and irregular posology. The meta‐regression showed larger VA gains with regular posology compared to an irregular posology, and decreased effect size as age increased. This meta‐analysis strongly suggests improved VA outcomes at 12 months in patients with wet AMD for 2.0 mg aflibercept, comparable to but slightly lower than landmark trials. Increased injection frequency and younger age demonstrates a trend with improved outcomes.
    Keyword
    aflibercept
    age-related macular degeneration
    anti-VEGF therapy
    meta-analysis
    visual acuity
    Identifier to cite or link to this item
    https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050336301&doi=10.1111%2faos.13825&partnerID=40&md5=9216a8d3eebac7684be393f8c79f7fea; http://hdl.handle.net/10713/10702
    ae974a485f413a2113503eed53cd6c53
    10.1111/aos.13825
    Scopus Count
    Collections
    UMB Open Access Articles 2019

    entitlement

    Related articles

    • Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    • Authors: Ba J, Peng RS, Xu D, Li YH, Shi H, Wang Q, Yu J
    • Issue date: 2015
    • Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing.
    • Authors: Szabo SM, Hedegaard M, Chan K, Thorlund K, Christensen R, Vorum H, Jansen JP
    • Issue date: 2015 Nov
    • Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register.
    • Authors: Lövestam Adrian M, Vassilev ZP, Westborg I
    • Issue date: 2019 Feb
    • Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    • Authors: Gillies MC, Nguyen V, Daien V, Arnold JJ, Morlet N, Barthelmes D
    • Issue date: 2016 Dec
    • Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
    • Authors: Lanzetta P, Cruess AF, Cohen SY, Slakter JS, Katz T, Sowade O, Zeitz O, Ahlers C, Mitchell P
    • Issue date: 2018 Dec
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.